Raymond James Cuts PHR as Call Buyers Bet the Other Way
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Why this matters: Raymond James just pulled its Outperform rating on PHR. The downgrade landed on a stock already down 10% in a week. Yet options traders moved in the opposite direction — aggressively.
Analysts Split After Earnings
The Q2 print on September 2 moved $11.84 down 6.25% on the day. The post-earnings analyst wave has been anything but uniform.
Raymond James analyst John Ransom cut to Market Perform from Outperform today. That's the headline negative. But the broader panel held firm. DA Davidson lowered its target to $13 from $14 while keeping its Buy. Baird actually raised its target to $11 from $10, maintaining Neutral. RBC Capital reiterated Outperform with a $19 target. Freedom Capital Markets and Needham both held Buy at $14.
The consensus sits at Hold with nine Hold ratings and two Outperform ratings. The mean target is $13.94 — a 27% premium to Friday's close of $10.94. The gap is real, but it reflects disagreement, not consensus optimism.
Options Traders Buy the Dip
The put/call ratio dropped to 0.14 on September 4 — a 52-week low. The 20-day average was 0.20. The z-score is -4.2, an extreme reading.
That means call buying spiked sharply immediately after earnings. Options traders are not hedging the downside. They're positioning for a recovery. The PCR had been remarkably stable between 0.20 and 0.22 for weeks before results. The break lower was abrupt and decisive.
This directly contradicts the direction of the Raymond James move. One desk is cutting conviction. Another is buying optionality on a bounce.
Borrow Market Stays Loose
The lending picture adds little urgency to the bear case. Availability sits at 5,609% — meaning roughly 44 million shares are available to borrow against just 2.7 million currently lent out. That is an extraordinarily loose market.
Cost to borrow is 0.57%, low in absolute terms. It had briefly spiked in early August before retreating. Short interest has fallen 22.9% over the past month, now at 4.5% of free float. Bears have been retreating since before earnings.
Nothing in the lending market points to renewed short aggression. The Raymond James downgrade cuts a rating — it doesn't build a borrow position.
What to Watch
Three signals are now pulling in different directions. Raymond James trimmed conviction on growth headwinds. Options traders bought calls at a 52-week extreme. Short sellers continued their retreat. The divergence between analyst caution and options positioning is the most interesting tension to track heading into the December 4 earnings date.
- Price: $10.94, down 10% on the week
- SI % of Free Float: 4.5%, down 22.9% over 30 days
- Availability: 5,609% (very loose)
- Cost to Borrow: 0.57%, falling
- PCR: 0.14 — 52-week low, z-score -4.2
- Analyst mean target: $13.94 (9 Hold, 2 Outperform)
- Raymond James: Downgrades to Market Perform from Outperform
- Next earnings: December 4, 2026
Stocks in this article
See the live data behind this article on ORTEX.
Open PHR on ORTEX →How this article was generated
- Generated
- 8 Sept 2026, 15:49
- Data as of
- 8 Sept 2026, 15:48
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesPrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.